Neuropathy Caused by Drugs

Peripheral Neuropathy

Volumn 2, Issue , 2005, Pages 2553-2583

  Herskovitz, Steven ^a   Schaumburg, Herbert H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34250747736     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-9491-7.50117-4     Document Type: Chapter

References (414)

1. Abarbanel J.M., Osiman A., Frisher S., Herishanu Y. Peripheral neuropathy and cerebellar syndrome associated with amiodarone therapy. Isr. J. Med. Sci. 1987, 23:893.
2. Ahmed A., Loes D.J., Bressler E.L. Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy. Neurology 1995, 45:588.
3. Albin R.L., Greenberg H.S., Townsend J.B., et al. Acute sensory neuropathy from pyridoxine overdose. Neurology 1986, 36:125.
4. Alston T.A. Neurotoxicity of metronidazole [letter]. Ann. Intern. Med. 1985, 103:161.
5. Anderson N.E., Lynch N.M., O'Brien K.P. Disabling neurologic complications of amiodarone. Aust. N. Z. J. Med. 1985, 15:300.
6. Anderson T.D., Davidovich A., Arceo R., et al. Peripheral neuropathy induced by 2', 3'-dideoxycytidine neurotoxicity. Lab. Invest. 1991, 66:63.
7. Anderson T.D., Davidovich A., Arezzo J., Brosnan C. Comparative neurotoxicity of dideoxycytidine in monkeys and rabbits. Toxicol. Lett. 1992, 191(Suppl.):1.
8. Ansbacher L.E., Bosch E.P., Cancilla P.A. Disulfiram neuropathy: a neurofilamentous distal axonopathy. Neurology 1982, 32:424.
9. Anzil A.P., Dozic S. Disulfiram neuropathy: an experimental study in the rat. J. Neuropathol. Exp. Neurol. 1978, 37:585.
10. Apfel S.C. Docetaxel neuropathy. Neurology 1996, 46:2.
11. Apfel S.C. Taxoids. Experimental and Clinical Neurotoxicology 2000, 1135. Oxford University Press, New York. P.S. Spencer, H.H. Schaumburg (Eds.).
12. Apfel S.C., Lipton R.B., Arezzo J.C., Kessler J.A. Nerve growth factor prevents toxic neuropathy in mice. Ann. Neurol. 1991, 29:87.
13. Aronson J.K. Positive inotropic drugs and drugs used in dysrhythmias. Myeler's Side Effects of Drugs 1992, 397. Elsevier, Amsterdam. 12th ed. M.N.G. DGBRes (Ed.).
14. Ayres R.C.S., Dousset B., Wixon S., et al. Peripheral neurotoxicity with tacrolimus. Lancet 1994, 343:862.
15. Bagchi D., Ray S.D., Patel D., Bagchi M. Protection against drug- and chemical-induced multiorgan toxicity by a novel IH636 grape seed proanthocyanidin extract. Drugs Exp. Clin. Res. 2001, 27:3.
16. Balakirev M.Y., Zimmer G. Mitochondrial injury by disulfiram: two different mechanisms of the mitochondrial permeability transition. Chem. Biol. Interact. 2001, 138:299.
17. Behar A., Livni N., Soffer D. Fine structure of sciatic nerves in nitrofurantoin polyneuropathy in rats. Neurotoxicology 1977, 4:13.
18. Behar A., Rachmilewistz F., Rahamimoff R., et al. Experimental nitrofurantoin polyneuropathy in rats. Arch. Neurol. 1965, 13:160.
19. Bell D.M. Neuropathy associated with furaltadone. JAMA 1961, 176:808.
20. Belongia E.A., Hedberg C.W., Gleich G.J., et al. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N. Engl. J. Med. 1990, 323:357.
21. Berger A.B., Arezzo J.C., Schaumburg H.H., et al. 2', 3'-Dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 1993, 43:358.
22. Berger A.B., Schaumburg H.H., Schroeder E., et al. Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity. Neurology 1992, 42:1367.
23. Bergouignan F.X., Vital C., Henry P., Eschapasse P. Disulfiram neuropathy. J. Neurol. 1988, 235:382.
24. Beuche W., Friede R.L. Remodeling of nerve structure in experimental isoniazid neuropathy in the rat. Brain 1986, 109:759.
25. Biehl J.P., Skavlem J.H. Toxicity of isoniazid. Am. Rev. Tuberc. 1953, 68:296.
26. Biehl J.P., Vilter R.W. Effects of isoniazid on pyridoxine metabolism. J. Am. Med. Assoc. 1954, 156:1549.
27. Bilbao J.M., Briggs S.J., Gray T.A. Filamentous axonopathy in disulfiram neuropathy. Ultrastruct. Pathol. 1984, 7:295.
28. Bissery M.C., Guenard D., Gueritte-Voegelein F., Lavelle F. Experimental antitumor activity of taxotere (RP56976, NSC 628503), a Taxol analogue. Cancer Res. 1991, 15:4845.
29. Bitton R.J., Figg W.D., Venzon D.J., et al. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. J. Clin. Oncol. 1995, 13:2223.
30. Balkemore W.F. Isoniazid. Experimental and Clinical Neurotoxicology 1980, 476. Williams & Wilkins, Baltimore. P.S. Spencer, H.H. Schaumburg (Eds.).
31. Bockhardt H., Drenckhahn D., Lullmann-Rauch R. Amiodarone-induced lipidosis-like alterations in ocular tissues of rats. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 1978, 207:91.
32. Borruat F.X., Regli R. Pseudotumor cerebri as a complication of amiodarone therapy. Am. J. Ophthalmol. 1993, 116:776.
33. Bouche P., Leger J.M., Lacomblez L., et al. Peripheral neuropathy during treatment with almitrine bismesylate: report of 28 cases. Muscle Nerve 1986, 9(Suppl.):122.
34. Bouche P., Leger J.M., Lacomblez L., et al. Peripheral neuropathies during treatment of almitrine: report of 46 cases. J. Neurol. 1989, 236:29.
35. Boulanouar A., Abdallah E., el Bakkali M., et al. Severe toxic optic neuropathies caused by isoniazid: apropos of 3 cases. J. Fr. Ophthalmol. 1995, 18:183.
36. Bouldin T.W., Hall C.D., Krigman M.R. Pathology of disulfiram neuropathy. Neuropathol. Appl. Neurobiol. 1980, 6:155.
37. Boyce E.G., Cookson E.T., Bond W.S. Persistent metronidazole-induced peripheral neuropathy. DICP 1990, 24:19.
38. Boyle F.M., Wheeler H.R., Shenfield G.M. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J. Neurooncol. 1999, 41:107.
39. Bradley W.G. The neuromyopathy of vincristine in the guinea pig. J. Neurol. Sci. 1970, 10:133.
40. Bradley W.G., Karlsson I.J., Rassol C.G. Metronidazole neuropathy. Br. Med. J. 1977, 2:610.
41. Bradley W.G., Lassman L.P., Pearce G.W., Walton J. The neuromyopathy of vincristine in man: clinical, electrophysiological and pathological studies. J. Neurol. Sci. 1970, 10:107.
42. Brazis P.W., Spivey J.R., Bolling J.P., Steers J.L. A case of bilateral optic neuropathy in a patient on tacrolimus (FK506) therapy after liver transplantation. Am. J. Ophthalmol. 2000, 129:536.
43. Brodsky J.B., Cohen E.N., Brown B.W., et al. Exposure to nitrous oxide and neurologic disease among dental professionals. Anesth. Analg. 1981, 60:297.
44. Bronster D.J., Yonover P., Stein J., et al. Demyelinating sensorimotor polyneuropathy after administration of FK506. Transplantation 1995, 59:1066.
45. Burch T., Ahburn L. Experimental therapy of onchocerciasis with suramin and hetrazan: results of a three year study. Am. J. Trop. Med. Hyg. 1951, 31:617.
46. Burns S.M., Lange D.J., Jaffe I., Hays A.P. Axonal neuropathy in eosinophilia-myalgia syndrome. Muscle Nerve 1994, 17:293.
47. Campana W.M., Eskeland N., Calcutt N.A., et al. Prosaptide prevents paclitaxel neuroxicity. Neurotoxicology 1998, 19:237.
48. Capri G., Munzone E., Tarenzi E., et al. Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J. Natl. Cancer Inst. 1994, 20:1099.
49. Carella F., Riva E., Morandi L., et al. Myopathy during amiodarone treatment: a case report. Ital. J. Neurol. Sci. 1987, 8:605.
50. Casey E.B., Jellife A.M., LeQuesne P.M., Millet Y.L. Vincristine neuropathy: clinical and electrophysiological observations. Brain 1973, 96:69.
51. Cavaletti G., Bogliun G., Marzorati L., et al. Peripheral neurotoxicity of Taxol in patients previously treated with cisplatin. Cancer 1995, 75:1141.
52. Cavaletti G., Cavaletti E., Montaguti P., et al. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 1997, 18:137.
53. Cavaletti G., Cavaletti E., Oggioni N., et al. Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology 2000, 21:389.
54. Cavaletti G., Tredici G., Braga M., Tazzari S. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of Taxol. Exp. Neurol. 1995, 133:64.
55. Cavanagh J.B. On the pattern of change in peripheral nerves produced by isoniazid intoxication in rats. J. Neurol. Neurosurg. Psychiatry 1964, 30:219.
56. Centers for Disease Control Eosinophilia-myalgia syndrome: New Mexico. MMWR Morb. Mortal. Wkly. Rep. 1989, 38:765.
57. Chan S.Y., Worth R., Ochs S. Block of axonplasmic transport in vitro by vinca alkaloids. J. Neurobiol. 1980, 11:251.
58. Chan T.Y., Critchley J.A. Usage and adverse effects of Chinese herbal medicines. Hum. Exp. Toxicol. 1996, 15:5.
59. Chang E., Dellon A.E., Dellon E.S., Hendrickson M.E. Developing a model of colchicine neuropathy. Microsurgery 2002, 22:46.
60. Chang L.W., Yang C.M., Chen C.F., Deng J.F. Experimental podophyllotoxin (bajiaolian) poisoning: I. Effects on the nervous system. Biomed. Environ. Sci. 1992, 5:283.
61. Chang L.W., Yang C.M., Chen C.F., Deng J.F. Experimental podophyllotoxin (bajiaolian) poisoning: effects on the liver, intestine, kidney, pancreas and testis. Biomed. Environ. Sci. 1992, 5:293.
62. Chang M.H., Lin K.P., Wu Z.A., Liao K.K. Acute ataxic sensory neuronopathy resulting from podophyllin intoxication. Muscle Nerve 1992, 15:513.
63. Chao C.F., Subjeck J.R., Johnson R.J. Behavioral and ultrastructural studies of desmethylmisonidazole-induced neurotoxicity in mice. Br. J. Radiol. 1983, 56:27.
64. Chapon F., Dupuy B., Gosset S., et al. Accidental poisoning with podophyllin: a case with study of peripheral nerve. Rev. Neurol. (Paris) 1991, 147:240.
65. Charness M.E., Moradi F., Scheinman M.M. Frequent neurologic toxicity associated with amiodarone therapy. Neurology 1984, 34:669.
66. Chattopadhyay M., Wolfe D., Huang S., et al. In vivo gene therapy for pyridoxine-induced neuropathy by herpes simplex virus-mediated gene transfer of neurotropin-3. Ann. Neurol. 2002, 51:19.
67. Chaudhry V., Chaudry M., Crawford T.M., et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003, 60:337.
68. Chaudhry V., Cornblath D., Corse A., et al. Thalidomide-induced neuropathy: clinical and electrophysiological features. Neurology 2002, 59:1872.
69. Chaudhry V., Eisenberger M.A., Sinibaldi V.J., et al. A prospective study of suramin-induced peripheral neuropathy. Brain 1996, 119:2039.
70. Chaudhry V., Rowinsky E.K., Sartorius S.E., et al. Peripheral neuropathy from Taxol and cisplatin combination chemotherapy: clinical and electro-physiological studies. Ann. Neurol. 1994, 35:204.
71. Chedru F., Nodzenski R., Dunand J.F., et al. Peripheral neuropathy during treatment with almitrine. Br. Med. J. (Clin Res. Ed.) 1985, 290:896.
72. Chen C., Vazquez-Padua M., Cheng Y. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Am. Soc. Pharmacol. Exp. Ther. 1991, 39:625.
73. Cherry C.L., Gahan M.E., McArthur J.C., et al. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J. AIDS 2002, 30:271.
74. Chokroverty S., Sayeed Z.A. Motor nerve conduction study in patients on diphenylhydantoin therapy. J. Neurol. Neurosurg. Psychiatry 1975, 38:1235.
75. Chu C.C., Huang C.C., Chu N.S. Sensory neuropathy due to Bajiaolian (podophyllotoxin) intoxication. Eur. Neurol. 2000, 44:121.
76. Chua C.L., Ohnishi A., Tateishi J., Kuroiwa Y. Morphometric evaluation of degenerative and regenerative changes in isoniazid-induced neuropathy. Acta Neuropathol. (Berl.) 1983, 60:183.
77. Cliffer K.D., Siuciak J.A., Carson S.R., et al. Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat. Ann. Neurol. 1998, 43:46.
78. Clouston P.D., Donnely P.E. Acute necrotising myopathy associated with amiodarone therapy. Aust. N. Z. J. Med. 1989, 19:483.
79. Collings H. Polyneuropathy associated with nitrofurantoin therapy. Arch. Neurol. 1960, 3:656.
80. Constantopoulos G., Rees S., Cragg B.G., et al. Effect of suramin on the activities of degradative enzymes of sphingolipids in rats. Res. Commun. Chem. Pathol. Pharmacol. 1981, 32:87.
81. Contreras P.C., Steffler C., Gruner J.A., et al. Insulinlike growth factor-I (RHIGF-I) prevents the peripheral neuropathy induced by paclitaxel, cisplatin, and vincristine [abstract]. Ann. Neurol. 1995, 38:315.
82. Cooper R.G., Evans D.A., Whibley E.J. Polymorphic hydroxylation of perhexilene maleate in man. J. Med. Genet. 1984, 21:27.
83. Costa-Jussa F.R., Guevara A., Brook G.A., et al. Changes in denervated skeletal muscle of amiodarone-fed mice. Muscle Nerve 1988, 11:627.
84. Costa-Jussa F.R., Jacobs J.M. The pathology of amiodarone neurotoxicity. I. Experimental studies with reference to changes in other tissues. Brain 1985, 108:735.
85. Coxon A., Pallis C.A. Metronidazole neuropathy. J. Neurol. Neurosurg. Psychiatry 1976, 39:403.
86. Crawford C.L. Use of thalidomide in leprosy. Toxicol. Rev. 1994, 13:177.
87. Crofford L.J., Rader J.I., Dalakas M.C., et al. L-tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat. J. Clin. Invest. 1990, 86:1757.
88. Dalton K., Dalton M.J.T. Characteristics of pyridoxine overdose neuropathy syndrome. Acta Neurol. Scand. 1987, 76:8.
89. Dano P., Tamman D., Brosset C., Bregigeon M. Peripheral neuropathies caused by disulfiram. Rev. Neurol. (Paris) 1996, 152:294.
90. 12 in rats by nitrous oxide. Lancet 1978, 2:1023.
91. DeDeyn P.P., Ceuterick C., Saxena V., et al. Chronic colchicine-induced myopathy and neuropathy. Acta Neurol. Belg. 1995, 95:29.
92. Diezel P.B. Morphologische veranderungen bei experimenteller Thalidomid-Neuropathie und thalidomide-bedingten: Extremitatenmissbildungen. Munchn. Med. Wochenschr. 1963, 105:2265.
93. Dische S., Saunders M.I., Lee M.E., et al. Clinical testing of the radio-sensitizer Ro-07-0582: experience with multiple doses. Br. J. Cancer 1977, 35:567.
94. Dobb G.J., Edis R.H. Coma and neuropathy after ingestion of herbal laxative containing podophyllin. Med. J. Aust. 1984, 140:495.
95. Dobkin B.H. Reversible subacute peripheral neuropathy induced by phenytoin. Arch. Neurol. 1977, 34:189.
96. Donofrio P.D., Stanton C., Miller V.S., et al. Demyelinating polyneuropathy in eosinophilia-myalgia syndrome. Muscle Nerve 1992, 15:796.
97. Draznin E., Rosenberg N.L. Intensive rehabilitation approach to eosinophilia myalgia associated with severe polyneuropathy. Arch. Phys. Med. Rehabil. 1993, 74:774.
98. Dreger L.M., Gleason P.P., Chowdhry T.K., Gazzuolo D.J. Intermittent-dose metronidazole-induced peripheral neuropathy. Ann. Pharmacother. 1998, 32:267.
99. Duarte J., Cabezas C., Rodrigues F., et al. Colchicine-induced myopathy with myotonia. Muscle Nerve 1998, 21:550.
100. Dubinsky R.M., Yarchoan R., Dalakas M., Broder S. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2', 3'-dideoxycytidine (ddC). Muscle Nerve 1989, 12:856.
101. Dudley W.H. Fatal podophyllin poisoning. Med. Rec. 1890, 37:409.
102. Duffy L.F., Daum F., Fisher S.E., et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985, 88:681.
103. Dupont P., Hunt I., Goldberg L., Warrens A. Colchicine myoneuropathy in a renal transplant patient. Transpl. Int. 2002, 15:374.
104. Dupuy O., Flocard F., Vial C., et al. Disulfiram (Esperal) toxicity: apropos of 3 original cases. Rev. Med. Interne 1995, 16:67.
105. DuVivier A., Fowler T. Possible dapsone-induced peripheral neuropathy in dermatitis herpetiformis. Proc. R. Soc. Med. 1974, 67:439.
106. Dyck P.J., Grina L.A., Lambert E.H., et al. Nitrous oxide neurotoxicity studies in man and rat. Anesthesiology 1980, 53:205.
107. Edwards M.S., Powers S.K., Baringer R.A., et al. Evoked potentials in rats with misonidazole toxicity. I. Brain stem auditory evoked potentials. J. Neurooncol. 1983, 1:115.
108. Eidelman B.H., Abu-Elmagd K., Wilson J., et al. Neurologic complications of FK-506. Transplant. Proc. 1991, 23:3175.
109. Eisen A.A., Woods J.F., Sherwin A.L. Peripheral nerve function in long-term therapy with diphenylhydantoin: a clinical and electrophysiologic correlation. Neurology 1974, 24:411.
110. Eisenberger M.A., Reyno L.M., Jodrell D.I., et al. Suramin, an active drug for prostate cancer: interim observations in a Phase 1 trial. J. Natl. Cancer Inst. 1993, 85:611.
111. Ellis F.G. Acute polyneuritis after nitrofurantoin therapy. Lancet 1962, 2:1136.
112. Emslie-Smith A.M., Engel A.G., Duffy J., Bowles C.A. Eosinophilia myalgia syndrome: 1. Immunocytochemical evidence for a T-cell mediated immune effector response. Ann. Neurol. 1991, 29:524.
113. Eneanya D.I., Bianchine J.R., Duran D.O., et al. The actions and metabolic fate of disulfiram. Annu. Rev. Pharmacol. Toxicol. 1981, 21:575.
114. Epstein F.W., Bohm M. Dapsone-induced peripheral neuropathy. Arch. Dermatol. 1976, 112:1761.
115. Estes M.L., Ewing-Wilson D., Chou S.M., et al. Chloroquine neuromyotoxicity. Am. J. Med. 1987, 82:447.
116. Evans T.S., Brochman E.J., Allan D., et al. Lack of peripheral neuropathy in beagle dogs after 53 weeks oral administration of thalidomide. Hum. Exp. Toxicol. 2000, 19:615.
117. Fardeau M., Tome F.M.S., Simon P. Muscle and nerve changes induced by perhexilene maleate in man and mice. Muscle Nerve 1979, 2:24.
118. Fazio R., Quattrini A., Bolognesi A., et al. Docetaxel neuropathy: a distal axonopathy. Acta Neuropathol. 1999, 98:651.
119. Feiner L.A., Younge B.R., Kazmier F.J., et al. Optic neuropathy and amiodarone therapy. Mayo Clin. Proc. 1987, 62:702.
120. Fernando-Roth R., Itabashi H., Louie J., et al. Amiodarone toxicity: myopathy and neuropathy. Am. Heart J. 1990, 119:1223.
121. Filley C.M., Graff-Radford N.R., Lacy J.R., et al. Neurologic manifestations of podophyllin toxicity. Neurology 1982, 32:308.
122. Fischl M.A., Olson R.M., Follansbee S.E., et al. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received the previous zidovudine therapy. Ann. Intern. Med. 1993, 118:762.
123. Forsyth P.A., Balmaceda C., Peterson K., et al. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J. Neurooncol. 1997, 35:47.
124. Fraser A.G., McQueen I.N.F., Watt A.H., Stephens M.R. Peripheral neuropathy during long-term high-dose amiodarone therapy. J. Neurol. Neurosurg. Psychiatry 1985, 48:576.
125. Fraser D.M., Campbell I.W., Miller H.C. Peripheral and autonomic neuropathy after treatment with perhexilene maleate. Br. Med. J. 1977, 2:675.
126. Freeman M.C., Weimer L.H., Arnaudo E., Brust J.C.M. Neuropathic and autonomic effects of intramuscular podophyllin. Ann. Neurol. 1997, 42:416.
127. Freilich R.J., Balmaceda C., Seidman A.D., et al. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996, 47:115.
128. Freimer M.L., Glass J.D., Chaudhry V., et al. Chronic demyelinating polyneuropathy associated with eosinophilia-myalgia syndrome. J. Neurol. Neurosurg. Psychiatry 1992, 55:352.
129. Frisoni G.B., DiMonda V. Disulfiram neuropathy: a review (1971-88) and report of a case. Alcohol Alcohol. 1989, 24:429.
130. Frytak S., Moertel C.G., Childs D.S., Albers J.W. Neurologic toxicity associated with high-dose metronidazole therapy. Ann. Intern. Med. 1978, 88:361.
131. Fuller R.K., Branchey L., Brightwell D.R., et al. Disulfiram treatment of alcoholism: a Veterans Administration Cooperative Study. JAMA 1986, 256:1449.
132. Fullerton P.M., Kremer M. Neuropathy after intake of thalidomide (Distaval). Br. Med. J. 1961, 2:855.
133. Fullerton P.M., O'Sullivan D.J. Thalidomide neuropathy: a clinical, electrophysiological, and histological follow-up study. J. Neurol. Neurosurg. Psychiatry 1968, 31:543.
134. Gammon G.D., Burge F.W., King G. Neural toxicity in tuberculous patients treated with isoniazid (isonicotinic acid hydrazide). Arch. Neurol. Psychiatry 1953, 70:64.
135. Gardner-Medwin J.M., Smith N.J., Powell R.J. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behceťs disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann. Rheum. Dis. 1994, 53:828.
136. Gherardi R., Benevenuti C., Lejong J.L., et al. Peripheral neuropathy in patients treated with almitrine dimesylate. Lancet 1985, 1:1247.
137. Gibson J.M., Fielder A.R., Garner A., Millac P. Severe ocular side effects of perhexilene maleate: case report. Br. J. Ophthalmol. 1984, 68:553.
138. Gill J.S., Hobday K.L., Windebank A.J. Mechanism of suramin toxicity in stable myelinating dorsal root ganglion cultures. Exp. Neurol. 1995, 133:113.
139. Gill J.S., Windebank A.J. Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons. Cell Death Differ. 1998, 5:876.
140. Godman G.C., Murray M.R. Influence of colchicine on the form of skeletal muscle in tissue culture. Proc. Soc. Exp. Biol. 1953, 84:668.
141. Gold B.G. Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders. Expert Opin. Invest. Drugs 2000, 9:2331.
142. Gorin F., Kindall D., Seyal M. Dorsal radiculopathy resulting from podophyllin toxicity. Neurology 1989, 39:607.
143. Grant A.C., Krendel D.A. Multifocal demyelinating neuropathy due to amiodarone [abstract]. Ann. Neurol. 1996, 40:539.
144. Green L.S., Donoso J.A., Heller-Bettinger I.E., Samson F.E. Axonal transport disturbances in vincristine-induced peripheral neuropathy. Ann. Neurol. 1977, 1:255.
145. Griffin J.W., Price D.L., Keuthe D.O., Goldberg A.M. Neurotoxicity of misonidazole in rats. I. Neuropathol. Neurotoxicol. 1979, 1:299.
146. Guiheneuc P., Ginet J., Groleau J.Y., Rojonan J. Early phase of vincristine neuropathy in man: electrophysiological evidence for a dying-back phenomenon, with transitory enhancement of spinal transmission of the monosynaptic reflex. J. Neurol. Sci. 1980, 45:355.
147. Guillaume S., Joachim M. Optic neuropathy from disulfiram (Antabuse): an observation. Bull. Soc. Belge Ophthalmol. 1998, 268:161.
148. Gutman L., Johnson D. Nitrous oxide-induced myeloneuropathy: report of cases. J. Am. Dent. Assoc. 1981, 103:239.
149. Guttmann L. Dapsone. Experimental and Clinical Neurotoxicology 2000, 464. Oxford University Press, New York. P.S. Spencer, H.H. Schaumburg (Eds.).
150. Guttmann L., Martin J.D., Welton W. Dapson motor neuropathy-an axonal disease. Neurology 1976, 26:524.
151. Hahn A.F., Feasby T.E. Metronidazole neuropathy-a sensory neuronopathy. Neurology 1989, 39(Suppl. 1):289.
152. Halloran T.J. Convulsions associated with high cumulative doses of metronidazole. Drug Intell. Clin. Pharmacol. 1982, 16:409.
153. Hamers F.P., Pette C., Neijt J.P., Gispen W.H. The ACTH-(4-9) analog, ORG 2766, prevents Taxol-induced neuropathy in rats. Eur. J. Pharmacol. 1993, 233:177.
154. Hauw J.J., Mussini J.M., Boutry J.M., et al. Perhexilene maleate induced lipidosis in human peripheral nerve and tissue culture: ultrastructural and biochemical changes. Clin. Toxicol. 1981, 18:1405.
155. Hayakawa K., Itoh T., Niwa H., et al. Nerve growth factor prevention of aged-rat sympathetic neuron injury by cisplatin, vincristine, and Taxol-in vitro explant study. Neurosci. Lett. 1999, 274:103.
156. Hayakawa K., Sobue G., Itoh T., Mitsuma T. Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine, and Taxol on rat sympathetic ganglion explants in vitro. Life Sci. 1994, 55:519.
157. Heath M.F., Costa-Jussa F.R., Jacobs J.M., Jacobson W. The induction of pulmonary phospholipidosis and the inhibition of lysosomal phospholipases by amiodarone. Br. J. Exp. Pathol. 1985, 66:391.
158. Heiman-Patterson T.D., Bird S.J., Parry G.J., et al. Peripheral neuropathy associated with eosinophilia-myalgia syndrome. Ann. Neurol. 1990, 28:522.
159. Helgren M.E., Cliffer K.D., Torrento K., et al. Neurotropin-3 administration attenuates deficits of pyrid-oxine-induced large-fiber sensory neuropathy. J. Neurosci. 1997, 17:322.
160. Heng J.E., Vorwerk C.K., Lessell E., et al. Ethambutol is toxic to retinal ganglion cells via an excitotoxic pathway. Invest. Ophthalomol. Vis. Sci. 1999, 40:190.
161. Herrick M.K., Chang Y., Horoupian D.S., et al. L-tryptophan and the eosinophilia-myalgia syndrome: pathologic findings in eight patients. Hum. Pathol. 1991, 22:12.
162. Hertzman P.A., Blevins W.L., Mayer J., et al. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N. Engl. J. Med. 1990, 322:869.
163. Hess C.W., Hunziker T., Kupfer A., Ludin H.P. Thalidomide-induced peripheral neuropathy: a prospective clinical, neurophysiological and pharmacogenetic evaluation. J. Neurol. 1986, 233:83.
164. Heyer E.J., Simpson D.M., Bodis-Wollner I., Diamond S.P. Nitrous oxide: clinical and electrophysio-logical investigation of neurological complications. Neurology 1986, 36:1618.
165. Hilkens P.H.E., Verweij J., Stoter G., et al. Peripheral neurotoxicity induced by docetaxel. Neurology 1996, 46:104.
166. Hilkens P.H.E., Verweij J., Vecht C.J., et al. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann. Oncol. 1997, 8:187.
167. Hinchey J., Chaves C., Appignani B., et al. A reversible posterior leGBRoencephalopathy syndrome. N. Engl. J. Med. 1996, 334:494.
168. Hogan-Dann C., Fellmeth W.G., McGuire A.S., Kiley V.A. Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome. JAMA 1984, 252:2862.
169. Holtzer H., Forry-Schaudies S., Dlugosz A., et al. Interactions between IF's, microtubules, and myofibrils in fibrogenic and myogenic cells. Ann. N. Y. Acad. Sci. 1985, 455:106.
170. Homeida M., Babikr A., Daneshmend T.K. Dapsone-induced optic atrophy and motor neuropathy. Br. Med. J. 1980, 281:1180.
171. Horlen C.K., Seifert C.F., Malouf C.S. Toxic metronidazole-induced MRI changes. Ann. Pharmacother. 2000, 34:1273.
172. Horowitz J.D., Sia S.T., MacDonald P.S., et al. Perhexilene maleate treatment for severe angina pectoris-correlations with pharmacokinetics. Int. J. Cardiol. 1986, 13:219.
173. Hughes H.B., Biehl J.P., Jones A.P., Schmidt L.H. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am. Rev. Tuberc. Pulm. Dis. 1954, 70:266.
174. Iniguez C., Larrode P., Mayordomo J.I., et al. Reversible peripheral neuropathy induced by a single administration of high-dose paclitaxel. Neurology 1998, 51:868.
175. Jacobs J.M., Costa-Jussa F.R. The pathology of amio-darone neurotoxicity. II. Peripheral neuropathy in man. Brain 1985, 108:753.
176. Jacobs J.M., Miller R.H., Cavanagh J.B. The distribution of degenerative changes in INH neuropathy: further evidence for focal axonal lesions. Acta. Neuropathol. (Berl.) 1979, 48:1.
177. Jerian S.M., Sarosy G.A., Link C.J., et al. Incapacitating autonomic neuropathy precipitated by Taxol. Gynecol. Oncol. 1993, 51:277.
178. Jones D.H., Bleehen N.M., Workman P., Smith N.C. The role of microsomal enzyme inducers in the reduction of misonidazole neurotoxicity. Br. J. Radiol. 1983, 56:865.
179. Jones W.A., Jones G.P. Peripheral neuropathy due to isoniazid: report of two cases. Lancet 1953, 1:1073.
180. Kamala A.N., Shetty V.P., Antia N.H. Evaluation of the neurotoxicity of dapsone in the mouse model. Indian J. Lepr. 1984, 56:251.
181. Kao W.F., Hung D.Z., Tsai W.J., et al. Podophyllotoxin intoxication: toxic effect of Bajiaolian in herbal therapeutics. Hum. Exp. Toxicol. 1992, 11:480.
182. Kaplan I.W. Condyloma acuminata. New Orl. Med. Surg. J. 1942, 94:388.
183. Kaplan J.G., Einzig A.I., Schaumburg H.H. Taxol causes permanent large fiber peripheral nerve dysfunction: a lesson for preventative strategies. J. Neurooncol. 1993, 16:105.
184. Kapoor K., Chandra M., Nag D., et al. Evaluation of metronidazole toxicity: a prospective study. Int. J. Clin. Pharmacol. Res. 1999, 19:83.
185. Karamanakos P.N., Pappas P., Stephanou P., Marselos M. Differentiation of disulfiram effects on central catecholamines and hepatic ethanol metabolism. Pharmacol. Toxicol. 2001, 88:106.
186. Kasik J.E. Tuberculosis and other mycobacterial diseases. Conn's Current Therapy 1994, 217. W. B. Saunders, Philadelphia. R.E. Rakel (Ed.).
187. Kaufman L.D., Kaufman M.A., Krupp L.B. Movement disorders in the eosinophilia-myalgia syndrome: tremor, myoclonus, and myokymia. J. Rheumatol. 1995, 22:157.
188. Keswani S.C., Chander B., Hasan C., et al. FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann. Neurol. 2003, 53:57.
189. Kilpatrick T.J., Phan S., Reardon K., et al. LeGBRemia inhibitory factor abrogates paclitaxel-induced axonal atrophy in the Wistar rat. Brain Res. 2001, 911:163.
190. Kitson T.M. The disulfiram-ethanol reaction. J. Stud. Alcohol 1977, 38:96.
191. Klinghardt G.W. Ein beitrag der experimentellen neuropathology zur toxizitatsprufung neuer chemotherapeutica. Mitt. Max Planck Ges. 1965, 3:142.
192. Kodavanti P.R.S., Pentlyala S.N., Yallpragada R., Desaiah D. Amiodarone and desethylamiodarone increase intrasynaptosomal free calcium through receptor mediated channel. Naunyn Schmeidebergs Arch. Pharmacol. 1992, 345:213.
193. Koller W.C., Gehlmann L.K., Malkinson F.D., Davis F.A. Dapsone-induced peripheral neuropathy. Arch. Neurol. 1977, 36:644.
194. Kondo H., Osborne M.L., Kollhouse J.F., et al. Nitrous oxide has multiple deleterious effects on cobalamin metabolism and causes decreases in activity of both mammalian cobalamin dependent enzymes in rats. J. Clin. Invest. 1981, 67:1270.
195. Krauss J.K., Mohadjer M., Wakhloo A.K., Mundinger F. Dystonia and akinesis due to pallidoputaminal lesions after disulfiram intoxication. Mov. Disord. 1991, 6:166.
196. 6 in rat primary sensory neurons. J. Neuropathol. Exp. Neurol. 1985, 44:117.
197. Krinke G., Schaumburg H.H., Spencer P.S., et al. Pyridoxine mega-vitaminosis produces degeneration of peripheral sensory neurons (sensory neuronopathy) in the dog. Neurotoxicology 1981, 2:13.
198. Kuncl R.W., Cornblath D.R., Avila O., Duncan G. Electrodiagnosis of human colchicine myoneuropathy. Muscle Nerve 1989, 12:360.
199. Kuncl R.W., Duncan G. Chronic human colchicine myopathy and neuropathy. Arch. Neurol. 1988, 45:245.
200. Kuncl R.W., Duncan G., Watson D., et al. Colchicine myopathy and neuropathy. N. Engl. J. Med. 1987, 316:1562.
201. Kusumi R.K., Plouffe J.F., Wyatt R.H., Fass R.J. Central nervous system toxicity associated with metronidazole therapy. Ann. Intern. Med. 1980, 93:59.
202. Lagueny A., Rommel A., Vignolly B., et al. Thalidomide neuropathy: an electrophysiological study. Muscle Nerve 1986, 9:837.
203. Laplane D., Attal N., Sauron B., et al. Lesions of basal ganglia due to disulfiram neurotoxicity. J. Neurol. Neurosurg. Psychiatry 1992, 55:925.
204. LaRocca R.V., Meer J., Gilliatt R.W., et al. Suramin-induced polyneuropathy. Neurology 1990, 40:954.
205. Latini R., Tognoni G., Kates R.E. Clinical pharma-cokinetics of amiodarone. Clin. Pharmacokinet. 1984, 9:136.
206. Layzer R.B. Myeloneuropathy after prolonged exposure to nitrous oxide. Lancet 1978, 2:1227.
207. Layzer R.B., Fishman B.A., Schafer J.A. Neuropathy following abuse of nitrous oxide. Neurology 1978, 28:504.
208. Learned-Coughlin S. Peripheral neuropathy induced by metronidazole. Ann. Pharmacother. 1994, 28:536.
209. Lee R.T., Oster M.W., Balmaceda C., et al. Bilateral facial nerve palsy secondary to the administration of high-dose paclitaxel. Ann. Oncol. 1999, 10:1245.
210. Leff R.S., Thompson J.M., Daly M.B., et al. Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma. Cancer 1988, 62:32.
211. Lehman T.J., Striegel K.H., Onel K.B. Thalidomide therapy for recalcitrant systemic onset juvenile rheumatic arthritis. J. Pediatr. 2002, 140:125.
212. Lemaire J.F., Autret A., Biziere K., et al. Amiodarone neuropathy: further arguments for human drug-induced neurolipidosis. Eur. Neurol. 1982, 21:65.
213. Lessell S. Histopathology of experimental ethambutol intoxication. Invest. Ophthalmol. 1976, 15:765.
214. LeQuesne P.M., Goldberg V., Vajda F. Acute conduction velocity changes in guinea pigs after administration of diphenylhydantoin. J. Neurol. Neurosurg. Psychiatry 1976, 39:995.
215. Letourneau P.C., Ressler A.H. Inhibition of neurite initiation and growth by Taxol. J. Cell Biol. 1984, 98:1355.
216. Lhermitte F., Fardeau M., Chedru F., Mallecourt J. Polyneuropathy after perhexilene maleate therapy. Br. Med. J. 1976, 1:1256.
217. Lhermitte F., Fritel D., Cambier J., et al. Polynevrites au cours traitements par la nitrofurantoine. Presse Med. 1963, 71:767.
218. Lipton R.B., Apfel S.C., Dutcher J.P., et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989, 39:368.
219. Lorentz I.T., Shortall M. Perhexilene neuropathy: a report of two cases. Aust. N. Z. J. Med. 1983, 13:517.
220. Love L.A., Rader J.I., Crofford L.J., et al. Pathological and immunological effects of ingesting L-tryptophan and 1, 1'-ethylidenebis (L-tryptophan) in Lewis rats. J. Clin. Invest. 1993, 91:804.
221. Lovelace R.E., Horwitz S.J. Peripheral neuropathy in long-term diphenylhydantoin therapy. Arch. Neurol. 1968, 18:69.
222. Lullmann H., Lullmann-Rauch R. Perhexilene induces generalized lipidosis in rats. Klin. Wochenschr. 1978, 56:309.
223. Lunsford J.M., Wynn M.H., Kwan W.H. Nitrous oxide-induced myeloneuropathy. J. Foot Surg. 1983, 22:222.
224. Lyon L.J., Nevins M.A., Fisch S., Henry S. Perhexilene maleate in treatment of angina pectoris. Lancet 1971, 1:1272.
225. Macaluso D.C., Shults W.T., Fraunfelder F.T. Features of amiodarone induced optic neuropathy. Am. J. Ophthalmol. 1999, 127:610.
226. MacDonald R.D., Engel A.G. Experimental chloroquine myopathy. J. Neuropathol. Exp. Neurol. 1973, 29:479.
227. Mahajan S.L. Acute acoustic nerve palsy associated with vincristine therapy. Cancer 1981, 42:2404.
228. Mamoli B., Wessely P., Kogelnik H.D., et al. Electroneurographic investigations of misonidazole polyneuropathy. Eur. Neurol. 1979, 18:405.
229. Mandell G.L., Sande M.A. Antimicrobial agents: drugs used in the chemotherapy of tuberculosis and leprosy. Goodman and Gilman's The Pharmacological Basis of Therapeutics 1993, 1146. McGraw-Hill, New York. 8th ed. A.G. Gilman, T.W. Rall, A.S. Nies, P. Taylor (Eds.).
230. Mann A., Sinnett M.J., Shinnar S. Phenytoin. Experimental and Clinical Neurotoxicology 2000, 988. Oxford University Press, New York. 2nd ed. P.S. Spencer, H.H. Schaumburg, A.C. Ludolph (Eds.).
231. Manolis A.S., Tordjman T., Mack K.D., Estes N.A. Atypical pulmonary and neurologic complications of amiodarone in the same patient: report of a case and review of the literature. Arch. Intern. Med. 1987, 147:1805.
232. Mansour A.M., PGBRlin J.E., O'Grady R. Optic nerve ultrastructure following amiodarone therapy. J. Clin. Neuroophthalmol. 1988, 8:231.
233. Marcus D.J., Swift T.R., McDonald T.F. Acute effects of phenytoin on peripheral nerve function in the rat. Muscle Nerve 1981, 4:48.
234. Marie R.M., LeBiez E., Busson P., et al. Nitrous oxide anesthesia-associated myelopathy. Arch. Neurol. 2000, 57:380.
235. Martinez-Arizala A., Sobol S.M., McCarty G.E., et al. Amiodarone neuropathy. Neurology 1983, 33:643.
236. Matsuoka Y., MGBRoyama M., Sobue I. Histopathological study of experimental ethambutol neuropathy. Clin. Neurol. 1972, 12:453.
237. Mayeno A.N., Belongia E.A., Lin F., et al. 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome?. Mayo Clin. Proc. 1992, 67:1134.
238. McCann S.R., Weir D.G., Dinn J., et al. Neurological damage induced by nitrous oxide in the monkey in the absence of any detectable haematological change. Br. J. Haematol. 1979, 43:496.
239. McCarthy B.G., Hsieh S.T., Stocks A., et al. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 1995, 45:1848.
240. McCombe P.A., van der Krecke S.A., Pender M.P. The effects of prophylactic cyclosporine A on experimental allergic neuritis (EAN) in the Lewis rat: induction of relapsing EAN using low-dose cyclosporine A. J. Neuroimmunol. 1990, 28:131.
241. McLeod J.G., Penny R. Vincristine neuropathy: an electrophysiological and histological study. J. Neurol. Neurosurg. Psychiatry 1969, 32:297.
242. McMorrow A.M., Adams R.J., Rubenstein M.N. Combined system disease after nitrous oxide anesthesia: a case report. Neurology 1995, 45:1224.
243. Medsger T.A. Tryptophan-induced eosinophilia-myalgia syndrome. N. Engl. J. Med. 1990, 322:926.
244. Mehrotra T.N., Srivastava S.S., Goel V.K., et al. A study of nerve conduction velocity in patients on diphenylhydantoin therapy. J. Assoc. Physicians India 1992, 40:619.
245. Meienberg O., Bajc O. Acute polyneuropathy caused by diphenylhydantoin intoxication. Dtsch. Med. Wochenschr. 1975, 100:1532.
246. Meier C., Kauer B., Mulle R.U., Ludin H.P. Neuromyopathy during chronic amiodarone treatment: a case report. J. Neurol. 1979, 220:231.
247. Meier C., Wahllaender A., Hess C.W., Preisig R. Perhexilene-induced lipidosis in the dark Agouti (DA) rat: an animal model of genetically determined neurotoxicity. Brain 1986, 109:649.
248. Meier-Ruge W.A., Schaumburg H.H. Chloroquine. Experimental and Clinical Neurotoxicology 2000, 375. Oxford University Press, New York. P.S. Spencer, H.H. Schaumburg (Eds.).
249. Melgaard B., Hansen H.S., Kamieniecka Z., et al. Misonidazole neuropathy: a clinical, electrophysiological, and histological study. Ann. Neurol. 1982, 12:10.
250. Melgaard B., Kohler O., Sand Hansen H., et al. Misonidazole neuropathy: a prospective study. J. Neurooncol. 1988, 6:227.
251. Merigan T.C., Skowron G. Safety and tolerance of dideoxycytidine as a single agent: results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Am. J. Med. 1990, 88:11S.
252. Mimura Y., Kato H., Eguchi K., Ogawa T. Schedule dependency of paclitaxel-induced neuropathy in mice: a morphological study. Neurotoxicology 2000, 21:513.
253. Mitrabhakdi E., Krauss G.R., Chaudhry V. Clinical and electro-physiological features of phenytoin-induced polyneuropathy. Muscle Nerve 1995, 18:1069.
254. MochizGBRi Y., Suyehiro Y., Tanizawa A., et al. Peripheral neuropathy in children on long-term phenytoin therapy. Brain Dev. 1981, 3:375.
255. Moddel G., Bilbao J.M., Payne D., Ashby P. Disulfiram neuropathy. Arch. Neurol. 1978, 35:658.
256. Mokri B., Ohnishi A., Dyck P.J. Disulfiram neuropathy. Neurology 1981, 31:730.
257. Molloy F.M., Floeter M.K., Syed N.A., et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 2001, 24:1050.
258. Montpetit V.J.A., Clapin D.F., Tryphonas L., Dancea S. Alteration of neuronal cytoskeletal organization in dorsal root ganglia associated with pyridoxine neurotoxi-city. Acta Neuropathol. 1988, 76:71.
259. Nair V.S., LeBrun M., Kass I. Peripheral neuropathy associated with ethambutol. Chest 1980, 77:98.
260. Nakata T., Yorifuji H. Morphological evidence of the inhibitory effect of Taxol on the fast axonal transport. Neurosci. Res. 1999, 35:113.
261. Navarro J.C., Rosales R.L., Ordinario A.T., et al. Acute dapsone-induced peripheral neuropathy. Muscle Nerve 1989, 12:604.
262. Nazarian S.M., Jay W.M. Bilateral optic neuropathy associated with amiodarone therapy. J. Clin. Neuroopthalmol. 1988, 8:25.
263. Nennesmo I., Reinholt F.P. Effects of intraneural injection of Taxol on retrograde axonal transport and morphology of corresponding nerve cell bodies. Virchows Arch. B Cell. Pathol. Mol. Pathol. 1988, 55:241.
264. New P.Z., Jackson C.E., Rinaldi D., et al. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996, 46:108.
265. Ng T.H., Chan Y.W., Yu Y.L., et al. Encephalopathy and neuropathy following ingestion of a Chinese herbal broth containing podophyllin. J. Neurol. Sci. 1991, 101:107.
266. NGBRada H., Pollock M. Disulfiram neuropathy: a morphometric study of sural nerve. J. Neurol. Sci. 1981, 51:51.
267. Ochoa J. Isoniazid neuropathy in man: quantitative electron microscopic study. Brain 1970, 93:831.
268. Ohnishi A., Chua C.L., Kuroiwa Y. Axonal degeneration distal to the site of accumulation of vesicular profiles in the myelinated fiber axon in experimental isoniazid neuropathy. Acta. Neuropathol. (Berl.) 1985, 67:195.
269. Olivera A.S., Calia L.C., Kiyomoto B.H., et al. Acute necrotizing myopathy and podophyllin toxicity: report of a fatal case. Arq. Neuropsiquiatr. 1996, 54:288.
270. Olney R.K., Miller R.G. Peripheral neuropathy associated with disulfiram administration. Muscle Nerve 1980, 3:172.
271. O'Mahoney S., Keohane C., Jacobs J., et al. Neuropathy due to podophyllin intoxication. J. Neurol. 1990, 237:110.
272. Pages M., Pages A.M. Peripheral nerve lesions in chloroquine-induced neuromyopathies. Ann. Pathol. 1984, 4:289.
273. Palakurthy P.R., Iyer V., Meckler R.J. Unusual neu-rotoxicity associated with amiodarone therapy. Arch. Intern. Med. 1987, 147:881.
274. Palliyath S.K., Schwartz B.D., Gant L. Peripheral nerve functions in chronic alcoholic patients on disulfiram: a six month follow up. J. Neurol. Neurosurg. Psychiatry 1990, 53:227.
275. Parry G.J., Bresden D.E. Neuropathy due to pyridoxine intoxication. Neurology 1985, 35:1466.
276. Paulson J.C., McClure W.O. Inhibition of axoplasmic transport by colchicine, podophyllotoxin, and vinblastine: an effect on microtubules. Ann. N. Y. Acad. Sci. 1975, 253:517.
277. Paulson O.B., Melgaard B., Hansen H.S., et al. Misonidazole neuropathy. Acta Neurol. Scand. Suppl. 1984, 100:133.
278. Pellissier J.F., Pouget J., Cros D., et al. Peripheral neuropathy induced by amiodarone chlorhydrate. J. Neurol. Sci. 1984, 63:251.
279. Pilcher J., Chandrasekhar K.P., Russell Rees J. Long term assessment of perhexilene maleate in angina pectoris. Postgrad. Med. J. 1973, 49:115.
280. Placidi G.F., MasoGBRa D., Alcaraz A., et al. Distribution and metabolism of 14C-metronidazole in mice. Arch. Int. Pharmacodyn. Ther. 1970, 188:168.
281. Pollet S., Hauw J.J., Escourolle R., Baumann N. Peripheral nerve lipid abnormalities in patients on perhexilene maleate. Lancet 1977, 1:1258.
282. Polomano R.C., Mannes A.J., Clark U.S., Bennett G.J. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 2001, 94:293.
283. Posada de la Paz M., Philen R.M., Borda A.I. Toxic oil syndrome: the perspective after 20 years. Epidemiol. Rev. 2001, 23:231.
284. Postma T.J., Vermoken J.B., Liefting A.J., et al. Paclitaxel-induced neuropathy. Ann. Oncol. 1995, 6:489.
285. Powell R.J., Gardner-Medwin J.M. Guidelines for the clinical use and dispensing of thalidomide. Postgrad. Med. 1994, 70:901.
286. Prakash V., Timasheff S.N. Aging of tubulin at neutral pH: the destabilizing effect of vinca alkaloids. Arch. Biochem. Biophy. 1992, 295:137.
287. Pronk L.C., Hilkins P.H., van den Bent M.J., et al. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel. Anticancer Drugs 1998, 9:759.
288. Pulipaka U., Lacomis D., Omalu B. Amiodarone-induced neuromyopathy: three cases and a review of the literature. J. Clin. Neuromuscul. Dis. 2002, 3:97.
289. Raabe D.S. Treatment of variant angina pectoris with perhexilene maleate. Chest 1979, 75:152.
290. Rago R.P., Miles J.M., Sufit R.L., et al. Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy: association of suramin with mitochondrial toxicity in humans. Cancer 1994, 73:1954.
291. Rajagopalan R., Gurnani S. Inhibition of tubulin assembly by anti-leprosy drug dapsone. Biochem. Biophys. Res. Commun. 1983, 116:128.
292. Ramirez J.A., Mendell J.R., Warmolts J.R., Griggs R.C. Phenytoin neuropathy: structural changes in the sural nerve. Ann. Neurol. 1986, 19:162.
293. Rana S.S., Giuliani M.J., Oddis C.V., Lacomis D. Acute onset of colchicine myoneuropathy in cardiac transplant recipients: case studies of three patients. Clin. Neurol. Neurosurg. 1997, 99:266.
294. Rao D.G., Kane N.K., Oware A. Thalidomide neuropathy: role of F-wave monitoring. Muscle Nerve 2000, 23:1301.
295. Rao K.S.P., Fernando J.C., Ho I.K., Mehendale H.M. Neurotoxicity in rats following subchronic amiodarone treatment. Res. Commun. Chem. Pathol. Pharmacol. 1986, 52:217.
296. 2+-ATPase activities in rat brain synaptosomes. Cell Biochem. Funct. 1986, 4:143.
297. Reasor M.J., Ogle C.L., Walker E.R., Kacew S. Amiodarone-induced phospholipidosis in rat alveolar macrophages. Am. Rev. Respir. Dis. 1988, 137:510.
298. Richardson P., Hideshima T., Anderson K. Thalidomide: emerging role in cancer medicine. Annu. Rev. Med. 2002, 53:629.
299. Riggs J.E., Schochet S.S., Gutmann L., et al. Chronic human colchicine neuropathy and myopathy. Arch. Neurol. 1986, 43:521.
300. Robberecht W., Bednarik J., Bourgeois P., et al. Myasthenic syndrome caused by direct effect of chloro-quine on neuromuscular junction. Arch. Neurol. 1989, 46:464.
301. Roden D.M. Antiarrhythmic drugs. The Pharmacologic Basis of Therapeutics 1996, 858. Pergamon, New York. 9th ed. L.S. Goodman, A. Gilman (Eds.).
302. Rosenberg H., Orkin F.K., Springstead J. Abuse of nitrous oxide. Anesth. Analg. 1979, 58:104.
303. Ross R.R. Use of pyridoxine hydrochloride to prevent isoniazid toxicity. J. Am. Med. Assoc. 1958, 168:73.
304. Rothrock J.F., Johnson P.C., Rothrock S.M., Merkley R. Fulminant polyneuritis after overdose of disul-firam and ethanol. Neurology 1984, 34:357.
305. Rowinsky E.K., Donehower R.C. Paclitaxel (Taxol). N. Engl. J. Med. 1995, 332:1004.
306. Roytta M., Raine C.S. Taxol-induced neuropathy: chronic effects of local injection. J. Neurocytol. 1986, 15:483.
307. Russell J.W., Gill J.S., Sorenson E.J., et al. Suramin-induced neuropathy in an animal model. J. Neurol. Sci. 2001, 192:71.
308. Russell J.W., Windebank A.J., Podratz J.L. Role of nerve growth factor in suramin neurotoxicity studied in vitro. Ann. Neurol. 1994, 36:221.
309. Rutkove S.B., DeGirolami U., Preston D.C., et al. Myotonia in colchicine myoneuropathy. Muscle Nerve 1996, 19:870.
310. Sadoh D.R., Hawk J.L.M., Panayiotopoulos C.P. Chronodispersion in patients on thalidomide. Clin. Neurophysiol. 1999, 110:735.
311. Sagman D.L., Melamed J.C. L-tryptophan-induced eosinophilia-myalgia syndrome and myopathy. Neurology 1990, 40:1629.
312. Sahenk Z., Barohn R., New P., Mendell J.R. Taxol neuropathy: electrodiagnostic and sural nerve biopsy findings. Arch. Neurol. 1994, 51:726.
313. Sahenk Z., Brady S.T., Mendell J.R. Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve 1987, 10:80.
314. 2O cartridges through a whipped cream dispenser. Neurology 1978, 28:485.
315. Said G. Perhexilene neuropathy: a clinicopathological study. Ann. Neurol. 1978, 3:259.
316. Said G., Goasguen J., Laverdant C. Neuropathy in long term treatment with metronidazole. Rev. Neurol. 1978, 134:515.
317. Sanfeliu C., Wright J.M., Kim S.U. Neurotoxicity of isoniazid and its metabolites in cultures of mouse dorsal root ganglion neurons and hybrid neuronal cell line. Neurotoxicology 1999, 20:935.
318. Santoro L., Barbieri F., Nucciotti R., et al. Amiodarone-induced experimental acute neuropathy in rats. Muscle Nerve 1992, 15:788.
319. Sasai K., Shibamoto Y., Takahashi M., et al. Pharma-cokinetics of 2-nitroimidazole hypoxic cell radiosensitizers in rodent peripheral nerve tissue. Int. J. Radiat. Biol. 1990, 57:971.
320. Saunders M.E., Dische S., Anderson P., Flockhart I.R. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum. Br. J. Cancer 1978, 37(Suppl. III):268.
321. Scharer K. Selective alterations of Purkinje cells in the dog after oral administration of high doses of nitroimidazole derivatives [author's transl.]. Verh. Dtsch. Ges. Pathol. 1972, 56:407.
322. Schaumburg H.H., Kaplan J., Windebank A., et al. Sensory neuropathy from pyridoxine abuse: a new megavit-amin syndrome. N. Engl. J. Med. 1983, 309:445.
323. Schaumburg H.H., Ludolph A.C., Gold B.G. Tacrolimus. Experimental and Clinical Neurotoxicology 2000, 1131. Oxford University Press, New York. S. Spencer, H.H. Schaumburg (Eds.).
324. 12-deficient subjects?. JAMA 1986, 255:1605.
325. Schilling T., Henrich B., Kau R., et al. Paclitaxel administered over 3 hrfollowed by cisplatin in patients with advanced head and neck squamous cell carcinoma: a clinical Phase I study. Oncology 1997, 54:89.
326. Schindler K.S., Zurakowski D., Dryer E.B. Caspase inhibitors block zinc-chelator induced death or retinal ganglion cells. Neuroreport 2000, 11:2299.
327. Schmidt I.G., Schmidt L.H. Studies of the neurotoxicity of ethambutol and its racemate for the rhesus monkey. J. Neuropathol. Exp. Neurol. 1966, 25:40.
328. Schmued L.C., Albertson C.M., Andrews A., et al. Evaluation of brain and nerve pathology in rats chronically dosed with ddI or isoniazid. Neurotoxicol. Teratol. 1996, 18:555.
329. Schroder J.M., Matthiesen T. Experimental thalidomide neuropathy: the morphological correlate of reduced conduction velocity. Acta Neuropathol. 1985, 65:285.
330. Schutz H.J., Busse O., Vuia O. Polyneuropathy caused by disulfiram poisoning. Arch. Psychiatr. Nervenkr. 1983, 233:1.
331. Schwab B.W., Arezzo J.C., Paladino A.M., et al. Rabbit sural nerve responses to chronic treatment with thalidomide and supidimide. Muscle Nerve 1984, 7:362.
332. Scott J.M., Wilson P., Dinn J.J, Weir D.G. Pathogenesis of subacute combined degeneration: a result of methyl group deficiency. Lancet 1981, 2:362.
333. Sebille A. Prevalence of latent perhexilene neuropathy. Br. Med. J. 1978, 2:1321.
334. Seguin P., Camus C., Leroy J.P., et al. Respiratory failure associated with hydroxychloroquine neuromyopathy. Eur. Neurol. 1995, 35:236.
335. Seiden D. Effects of colchicine on myofilament arrangement and the lysosomal system in skeletal muscle. Z. Zellforsch. 1973, 144:467.
336. Selwa J.F., Feldman E.L., Blaivas M. Mononeuropathy multiplex in tryptophan-associated eosinophilia-myalgia syndrome. Neurology 1990, 40:1632.
337. Sghirlanzoni A., Mantegazza R., Mora M., et al. Chloroquine myopathy and myasthenia-like syndrome. Muscle Nerve 1988, 11:114.
338. Shah R.R., Oates N.S., Idle J.R., et al. Impaired oxidation of debrisoquine in patients with perhexilene neuropathy. Br. Med. J. (Clin. Res. Ed.) 1982, 1:295.
339. Shah R.R., Oates N.S., Idle J.R., et al. Prediction of subclinical perhexilene neuropathy in a patient with inborn error of debrisoquine hydroxylation. Am. Heart J. 1983, 105:159.
340. Shields R.W. Peripheral neuropathies. Conn's Current Therapy 1996, 915. W. B. Saunders, Philadelphia. R.E. Rakel (Ed.).
341. Shorvon S.D., Reynolds E.H. Anticonvulsant peripheral neuropathy: a clinical and electrophysiological study of patients on single drug treatment with phenytoin, carbamazepine or barbiturates. J. Neurol. Neurosurg. Psychiatry 1982, 45:620.
342. Silver R.M., Sutherland S.E., Carreira P., Heyes M.P. A murine model of the eosinophilia-myalgia syndrome induced by 1, 1'-ethylidenebis (L-tryptophan). J. Clin. Invest. 1994, 93:1473.
343. Singh N.T., Pesantl E.L. Tuberculosis and other mycobacterial disease. Conn's Current Therapy 1996, 226. W. B. Saunders, Philadelphia. R.E. Rakel (Ed.).
344. Singlas E., Goujet M.A., Simon P. Pharmacokinetics of perhexilene maleate in anginal patients with and without peripheral neuropathy. Eur. J. Clin. Pharmacol. 1978, 14:195.
345. Sirsat A.M., Lalitha V.S., Pandya S.S. Dapsone neuropathy-report of three cases and pathologic features of a motor nerve. Int. J. Lepr. Other Mycobact. Dis. 1987, 55:23.
346. Smith B.E., Dyck P.J. Peripheral neuropathy in the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Neurology 1990, 40:1035.
347. Soliven B., Dhand U.K., Kobayashi K., et al. Evaluation of neuropathy in patients on suramin treatment. Muscle Nerve 1997, 20:83.
348. Stacy C.B., DiRocco A., Gould R.J. Methionine in the treatment of nitrous-oxide induced neuropathy and myeloneuropathy. J. Neurol. 1992, 239:401.
349. Stahlberg D., Barany F., Elinarsson K., et al. Neurophysiologic studies of patients with Crohn's disease on long-term treatment with metronidazole. Scand. J. Gastroenterol. 1991, 26:219.
350. Stein M., Bell M.J., Ang L.C. Hydroxychloroquine neuromyotoxicity. J. Rheumatol. 2000, 27:2927.
351. Stephens W.P., Eddy J.D., Parson I.M., Singh S.P. Raised intracranial pressure due to perhexilene maleate. Br. Med. J. 1978, 1:21.
352. Stevenson M.A., Calderwood S.K., Coleman C.N. Effects of nitro-imidazoles on neuronal cells in vitro. Int. J. Radiat. Oncol. Biol. Phys. 1989, 16:1225.
353. Sugita H., Higuchi I., Sano M., Ishiura S. Trial of a cysteine proteinase inhibitor, EST, in experimental chloro-quine myopathy in rats. Muscle Nerve 1987, 10:516.
354. Sullivan M., Follis R.H., Hilgartne M. Toxicology of podophyllin. Proc. Soc. Exp. Biol. Med. 1951, 77:269.
355. Swift T.R., Gross J.A., Ward L.C., Crout B.O. Peripheral neuropathy in epileptic patients. Neurology 1981, 31:826.
356. Swygert L.A., Back E.E., Auerbach S.B., et al. Eosinophilia-myalgia syndrome: mortality data from the U.S. National Surveillance System. J. Rheumatol. 1993, 20:1711.
357. Swygert L.A., Maes E.F., Sewell L.E., et al. Eosinophilia-myalgia syndrome: results of national surveillance. JAMA 1990, 264:1698.
358. Takeuchi H., Yamada A., Touge T., et al. Metronidazole neuropathy: a case report. Jpn. J. Psychiatry Neurol. 1988, 42:291.
359. Tanhehco J.L., Weichers D.O., Golbus J., Neeley S.E. Eosinophilia-myalgia syndrome: myopathic electrodiagnostic characteristics. Muscle Nerve 1992, 15:561.
360. Tapal M.F. Colchicine myopathy. Scand. J. Rheumatol. 1996, 25:105.
361. Taylor J.W., Murphy M.J., Rivey M.P. Clinical and electrophysiologic evaluation of peripheral nerve function in chronic phenytoin therapy. Epilepsia 1985, 26:416.
362. Tegner R., Tome F.M., Godeau P., et al. Morphological study of peripheral nerve changes induced by chloroquine treatment. Acta Neuropathol. 1988, 75:253.
363. Tester-Dalderup C.B.M. Metronidazole and related compounds. Myeler's Side Effects of Drugs 1992, 705. Elsevier, Amsterdam. 12th ed. M.N.G. DGBRes (Ed.).
364. Thant M., Hawley R.J., Smith M.T., et al. Possible enhancement of vincristine neuropathy by VP-16. Cancer 1982, 49:859.
365. Tomczak R.L., Hake D.H. Near fatal systemic toxicity from local injection of podophyllin for pedal verrucae treatment. J. Foot Surg. 1992, 31:36.
366. Tomlinson I.W., Rosenthal F.D. Proximal myopathy after perhexilene maleate treatment. Br. Med. J. 1977, 1:1319.
367. Tonkin E.G., Erve J.C., Valentine W.M. Disulfiram produces a non-carbon disulfide-dependent schwannopathy in the rat. J. Neuropathol. Exp. Neurol. 2000, 59:786.
368. Toole J.F., Gergen J.A., Hayes D.M., et al. Neural effects of nitrofurantoin. Arch. Neurol. 1968, 18:680.
369. Toole J.F., Parrish M.L. Nitrofurantoin polyneuropathy. Neurology 1973, 23:554.
370. Tugwell P., James S.L. Peripheral neuropathy with ethambutol. Postgrad. Med. 1972, 48:667.
371. Turi G.K., Solitaire G.B., James N., Dicker R. Eosinophilia-myalgia syndrome (L-tryptophan-associated neuromyopathy). Neurology 1990, 40:1793.
372. Unger S.A., Robinson M.A., Horowitz J.D. Perhexilene improves symptomatic status in elderly patients with severe aortic stenosis. Aust. N. Z. J. Med. 1997, 27:24.
373. Urtasan R.C., Chapman J.D., Feldstein M.L., et al. Peripheral neuropathy related to misonidazole: incidence and pathology. Br. J. Cancer 1978, 37(Suppl. III):271.
374. Urtasan R.C., Rabin H.R., Partington J. Human pharmacokinetics and toxicity of high-dose metronidazole administered orally and intravenously. Surgery 1983, 93:145.
375. Vahdat L., Papadopoulos K., Lange D., et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin. Cancer Res. 2001, 7:1192.
376. van den Bent M.J., Hilkens P.H., Sillevis Smitt P.A., et al. Lhermitte's sign following chemotherapy with docetaxel. Neurology 1998, 50:563.
377. van den Bent M.J., van Raaij-van den Aarssen V.J., Verweij J., et al. Progression of paclitaxel-induced neuropathy following discontinuation of treatment. Muscle Nerve 1997, 20:750.
378. Van Rossum J., Ross R.A., Bots G.T. Disulfiram polyneuropathy. Clin. Neurol. Neurosurg. 1984, 86:81.
379. Vishnubhakat S.M., Beresford H.R. Reversible myeloneuropathy of nitrous oxide abuse: serial electrophysio-logical studies. Muscle Nerve 1991, 14:22.
380. von Rogulja P., Kovac W., Schmid H. Metronidazole encephalopathy in rats. Acta Neuropathol. (Berl.) 1973, 25:36.
381. Vrobel T.R., Miller P.E., Mostow N.D., Rakita L. A general overview of amiodarone toxicity: its prevention, detection, and management. Prog. Cardiovasc. Dis. 1989, 31:393.
382. Waldinger T.P., Siegle R.J., Weber W., Voorhees J.J. Dapsone-induced peripheral neuropathy: case report and review. Arch. Dermatol. 1984, 120:356.
383. Wang M.S., Davis A.A., Culver D.G., Glass J.D. Wld mice are resistant to paclitaxel (Taxol) neuropathy. Ann. Neurol. 2002, 52:442.
384. Wang M.S., Fang G., Culver D.G., et al. The WldS protein protects against axonal degeneration: a model of gene therapy for peripheral neuropathy. Ann. Neurol. 2001, 50:773.
385. Wasay M., Wolfe G.E., Herrold J.M., et al. Chloroquine myopathy and neuropathy with elevated CSF protein. Neurology 1998, 51:1226.
386. Watson C.P., Ashby P., Bilbao J.M. Disulfiram neuropathy. Can. Med. Assoc. J. 1980, 123:123.
387. Weller A., Rosenberg N., Schlitz P., et al. Tryptophan causes EMS-like skin changes and induction of ICAM and LFA in SJL/J mice. J. Immunol. 1993, 150:172A.
388. Werner E.G., Olanow C.W. Parkinsonism and amio-darone therapy. Neurology 1989, 25:630.
389. Whisnant J.P., Espinosa R.E., Kierland R.R., Lambert E.H. Chloroquine neuromyopathy. Proc. Mayo Clin. 1963, 38:501.
390. Wijdicks E.F.M., Wiesner R.H., Dahlke L.J., Krom R.A.F. FK-506-induced neurotoxicity in liver transplantation. Ann. Neurol. 1994, 35:498.
391. Wijesekera J.C., Critchley E.M.R., Fahim Y., et al. Peripheral neuropathy due to perhexilene maleate. J. Neurol. Sci. 1980, 46:303.
392. Williams M.E., Walker A.N., Bracikowski J.P., et al. Ascending myelo-encephalopathy due to intrathecal vincristine sulfate. Cancer 1983, 51:2041.
393. Williams M.H., Bradley W.G. An assessment of dapsone toxicity in the guinea pig. Br. J. Dermatol. 1972, 86:650.
394. Wilson J.R., Conwit R.A., Eidelman B.H., et al. Sensorimotor neuropathy resembling CIDP in patients receiving FK506. Muscle Nerve 1994, 17:528.
395. Wilson L., Bamburg J.R., Mizel S.B., et al. Interaction of drugs with microtubule proteins. Fed. Proc. 1974, 33:158.
396. Windebank A.J., Low P.A., Blexrud M.D. Pyridoxine neuropathy in rats: degeneration of sensory axons. Neurology 1985, 35:1617.
397. Wisniewski H., Shelanski M.L., Terry R.D. Effects of mitotic spindle inhibitors on neurotubules and neurofilaments in anterior horn cells. J. Cell Biol. 1968, 38:224.
398. Wright G.J., Leeson G.A., Zeiger A.V., Lang J.F. The absorption, excretion, and metabolism of perhexilene maleate by the human. Postgrad. Med. 1973, 49:8.
399. Wulff E.A., Wang A.K., Simpson D.M. HIV-associated peripheral neuropathy: epidemiology, pathophysiology, and treatment. Drugs 2000, 59:1251.
400. Wyatt E.H., Stevens J.C. Dapsone induced peripheral neuropathy. Br. J. Dermatol. 1972, 86:521.
401. Xu Y., Sladky J.T., Brown M.B. Dose-dependent expression of neuropathy after experimental pyridoxine intoxication. Neurology 1989, 39:1077.
402. Yakisich J.S., Siden A., Eneroth P., Cruz M. Disulfiram is a potent in vitro inhibitor of DNA topoiso-merases. Biochem. Biophys. Res. Commun. 2001, 289:586.
403. Yamaguchi T., Katoh I., Kurata S. Azidothymidine causes functional and structural destruction of mitochondria, glutathione deficiency and HIV-promotor sensitization. Eur. J. Biochem. 2002, 269:2782.
404. Yamamoto M., Sobue G., MGBRoyama M., et al. Demonstration of slow acetylator genotype of N-acetyltransferase in isoniazid neuropathy using an archival hematoxylin and eosin section of a sural nerve biopsy specimen. J. Neurol. Sci. 1996, 135:51.
405. Yamamoto T. Pathologic processes of lumbar primary sensory neurons produced by high doses of pyridoxine in rats-morphometric and electron microscopic studies. Sangyo Ika Daigaku Zasshi 1991, 13:109.
406. Yamanaka Y., Sakamoto E., Sakuma Y., et al. Lipidosis of the dorsal root ganglia in rats with almitrine metabolite. Arch. Toxicol. 1995, 69:391.
407. Yamanaka Y., Shimada T., MochizGBRi R., et al. Neuronal and muscular inclusions in rats with hindlimb dysfunction after treating with difluorobenzyhydrylpiperadine. Toxicol. Pathol. 1997, 25:150.
408. Yang C.M., Deng J.F., Chen C.F., Chang L.W. Experimental podophyllotoxin (bajiaolian) poisoning: III. Biochemical bases for toxic effects. Biomed. Environ. Sci. 1994, 7:259.
409. Yarchoan R., Perno C.R., Thomas R.V., et al. Phase I studies of 2', 3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988, 1:76.
410. Yiahn C.H., Paniello R.C., Gershon-Spector J. Inhibition of motor nerve regeneration in a rabbit facial nerve mode. Laryngoscope 2001, 111:786.
411. Yiannikas C., Pollard J.D., McLeod J.G. Nitrofurantoin neuropathy. Aust. N. Z. J. Med. 1981, 11:400.
412. Yoshikawa H., Abe T., Oda Y. Extremely acute phenytoin-induced peripheral neuropathy. Epilepsia 1999, 40:528.
413. Younger D.S., Mayer S.A., Weimer L.H., et al. Colchicine-induced myopathy and neuropathy. Neurology 1991, 41:943.
414. Zivkovic S.A., Lacomis D., Giuliani M.J. Sensory neuropathy associated with metronidazole: report of four cases and review of the literature. J. Clin. Neuromuscul. Dis. 2001, 3:8.